Clinical

ASH 2025 data on KLN-1010 suggest that off-the-shelf, in vivo CAR T therapy could significantly expand access to cellular therapy in multiple myeloma by reducing manufacturing, treatment delays, and logistical barriers, provided toxicity remains manageable.

ASH 2025 data emphasize that standardized protocols and strong academic-community communication are essential for safe and consistent management of bispecific antibody adverse events in community oncology.

A Maui Derm 2026 session explored advancements in pediatric dermatology, emphasizing precision medicine and targeted therapies for children.

Speakers delved into innovative strategies in skin tumor management, focusing on chemotherapies, patient risk assessment, and evolving treatment protocols.

LLMs provide valuable answers to common Mohs surgery questions, supporting postoperative care and patient education without replacing physician guidance.

Explore the significance of patient-reported outcomes in cancer treatment, highlighting the benefits of zongertinib and its impact on quality of life.

Explore how evolving treatment strategies and biomarkers are transforming the management of HER2-positive breast cancer in clinical practice.

Dr. Hirsch discusses the promising efficacy and safety of cevertinib for HER2-mutant non-small cell lung cancer, highlighting its potential as a first-line treatment.

It seems there is no text provided for summarization. Please share the content you'd like summarized, and I'll be happy to help!

Experts discuss groundbreaking therapies in dermatology at Maui Derm 2026, addressing complex skin diseases and enhancing patient care with innovative treatments.

Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma with high response rates.

Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma with high response rates.

Almost half of the monthly-updated CDC databases had unexplained pauses in 2025, mostly affecting vaccination data, raising transparency and public health concerns.

ACE inhibitors may improve survival in IPF patients, highlighting potential repurposing of a common cardiovascular drug.

Maui Derm 2026 showcases groundbreaking clinical trial data and innovative strategies in dermatology.

Experts underscored that educating clinicians and the public about red flag CRC symptoms could facilitate earlier screening, diagnosis, and treatment.

Adults who are underweight, overweight, or obese face higher medical expenditures, varying by age, sex, and care setting.

Ongoing phase 3 trials target improved therapies for hematologic malignancies, focusing on CLL, multiple myeloma, and pediatric leukemia outcomes.

Dexamethasone pretreatment significantly reduces GI complications in DLBCL patients undergoing R-CHOP, maintaining efficacy and improving safety.

These findings support the potential role of ctDNA in prognostic assessment and early intervention.

Phase 2 trial results show anlotinib with anthracyclines and ifosfamide yields a 30.8% ORR and an 82.7% DCR in advanced soft tissue sarcoma.

There is a shift happening in mental health care, with real-world data and holistic evaluations improving patient outcomes and reducing disparities.

Oral nalbuphine significantly reduced cough frequency and severity in idiopathic pulmonary fibrosis (IPF), with patients seeing greater benefit at higher doses.

Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the promise of faster, less toxic treatment without lymphodepletion while raising important questions about durability, safety, and patient selection.